

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

RECEIVED  
SECRETARY OF THE SENATE  
PUBLIC RECORDS

03 AUG 14 PM 1:57

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name

Akin, Gump, Strauss, Hauer & Feld, L.L.P.

2. Address  Check if different than previously reported

1333 New Hampshire Avenue, NW

3. Principal Place of Business (if different from line 2)

City: Washington

State/Zip (or Country) DC 20036

4. Contact Name

Donald R. Pongrace

Telephone

202-887-4000

E-mail (optional)

5. Senate ID #

682-862

7. Client Name  Self

Pfizer, Inc.

6. House ID #

317840

**TYPE OF REPORT** 8. Year 2003 Midyear (January 1-June 30)  OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇨ Termination Date \_\_\_\_\_

11. No Lobbying

### INCOME OR EXPENSES – Complete Either Line 12 OR Line 13

#### 12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000

\$10,000 or more  ⇨ \$ 260,000  
Income (nearest \$20,000)

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

#### 13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000

\$10,000 or more  ⇨ \$ \_\_\_\_\_  
Expenses (nearest \$20,000)

14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of method.

Method A. Reporting amounts using LDA defined Internal Revenue Code

Method B. Reporting amounts under section 6011 Internal Revenue Code

Method C. Reporting amounts under section 162 Internal Revenue Code

Signature \_\_\_\_\_ Date August 13, 2008

Printed Name and Title Donald R. Pongrace, Partner

LD-2 (REV. 6/98)

P/

Registrant Name Akin, Gump, Strauss, Hauer & Feld, L.L.P. Client Name Pfizer, Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Medicare prescription drug benefit legislation, including H.R. 1, S. 1; H.R. 2427; H.R. 2769; H.R. 980, S


17. House(s) of Congress and Federal Agencies contacted  Check if None

- U.S. House of Representatives
- U.S. Senate
- U.S. Department of the Interior
- U.S. Department of Justice

18. Name of each individual who acted as a lobbyist in this issue area

Name (bolded names are new lobbyists)		Covered Official Position (if applicable)
Thaddeus Burns	Bill Paxon	
Stacy Carlson	Donald R. Pongrace	
Smith W. Davis	Paul G. Scolese	
Anthony Foti	Barney J. Skladany (new)	
Gary A. Heimberg		
Jorge Lopez, Jr.		
P. Vincent LoVoi		
Michael J. Parini		

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date August 14, 2003

